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Abstract The use of stimulants has important implica-
tions for HIV prevention and care. However, few
investigations have examined psychological correlates of
substance use and adherence to anti-retroviral therapy
(ART) among HIV-positive stimulant users. This cross-
sectional investigation examined affective correlates of
stimulant use and ART adherence among HIV-positive
methamphetamine users. In total, 122 HIV-positive men
who have sex with men or transgendered individuals on
ART who reported using methamphetamine in the past
30 days were recruited from the community. HIV-specific
traumatic stress was consistently and independently asso-
ciated with more frequent cocaine/crack use (but not with
methamphetamine use). Positive affect was independently
associated with a decreased likelihood of reporting any
injection drug use and an increased likelihood of reporting
perfect ART adherence. HIV-specific traumatic stress may
be an important determinant of increased cocaine/crack
use in this population. Positive affect may increase the
likelihood that individuals will refrain from injection drug
use and achieve high levels of ART adherence.
Keywords Cocaine  HIV/AIDS  Methamphetamine 
Positive affect  Trauma  Self medication hypothesis
Introduction
Stimulant use is associated with increased rates of HIV
transmission risk behavior, acquisition of strains of HIV
that are resistant to some classes of antiretroviral medica-
tions, impaired adherence to anti-retroviral therapy (ART),
and elevated HIV viral load (Carrico et al. 2007; Colfax
et al. 2007; Gorbach et al. 2008; Hinkin et al. 2007;
Johnson et al. 2008; Morin et al. 2007). Consequently,
stimulant users have been identified as an important group
to target for HIV prevention efforts. There is some pre-
liminary evidence that behavioral interventions designed to
enhance motivation as well as bolster self-efficacy for
reducing sexual risk taking are effective in decreasing HIV
transmission risk behavior in methamphetamine users
(Mausbach et al. 2007). However, little is known about the
role of potentially modifiable psychological factors (like
affective states) in relation to substance use and ART
adherence among HIV-positive stimulant users. In a prior
cross-sectional investigation, we observed that enhanced
affect regulation was indirectly associated with lower HIV
viral load via two independent behavioral pathways, a
decreased likelihood of reporting regular stimulant use and
better self-reported ART adherence (Carrico et al. 2007).
Although these findings are informative, further investi-
gations are needed to examine specific affective correlates
of these important health behaviors in HIV-positive stim-
ulant users.
A. W. Carrico (&)  M. O. Johnson
Center for AIDS Prevention Studies, University of California,
San Francisco, 50 Beale St., Suite 1300, San Francisco,
CA 94105, USA
e-mail: adam.carrico@ucsf.edu
G. N. Colfax
San Francisco Department of Public Health, AIDS Office,
San Francisco, CA, USA
G. N. Colfax
Positive Health Program, San Francisco General Hospital,
San Francisco, CA, USA
J. T. Moskowitz
Osher Center for Integrative Medicine, University of California,
San Francisco, CA, USA
123
AIDS Behav (2010) 14:769–777
DOI 10.1007/s10461-008-9513-y
HIV-specific Traumatic Stress and Negative Affect
There is increasing recognition that individuals may expe-
rience HIV-specific traumatic stress, symptoms of post-
traumatic stress disorder (PTSD) that stem from the expe-
rience of living with HIV/AIDS (Delahanty et al. 2004;
Semple et al. 2002). HIV-specific traumatic stress and
negative affect may have important implications for self-
regulation of a variety of behaviors, including substance use.
Consistent with the self medication hypothesis
(Khantzian 1997), emerging empirical evidence from clin-
ical investigations indicates that one core feature of
substance use disorders appears to be difficulties with
awareness or tolerance of internal experiences that can
serve as triggers for continued substance use (Carrico et al.
2007; Gifford et al. 2006; Hayes et al. 1996; Morgenstern
et al. 1997; O’Cleirigh et al. 2007). This is further supported
by the results of one qualitative investigation where HIV-
positive methamphetamine users on ART reported that
using methamphetamine provided a temporary respite from
intrusive thoughts (an important PTSD symptom) about
their HIV serostatus (Semple et al. 2002). Although sub-
stance use may allow individuals to avoid intrusive thoughts
or negative mood states in the short-term, increases in
depressive symptoms are commonly observed over time
(Kosten et al. 1998). Elevated depressive symptoms, in turn,
predict continued substance use as well as relapse to sub-
stance use across a variety of populations (Baker 2006;
Baker et al. 2004). Taken together, results of these inves-
tigations indicate that HIV-specific traumatic stress and
negative affect may be important triggers for stimulant use.
Other investigations have examined the extent to which
negative affect and PTSD symptoms may impair the
capacity of individuals to effectively adhere to ART regi-
mens. There is burgeoning evidence that depressive
symptoms and other forms of negative affect are directly or
indirectly associated with ART non-adherence (Johnson
et al. 2003; Starace et al. 2002; Weaver et al. 2005).
However, investigations examining whether PTSD symp-
toms are independently related to ART non-adherence have
obtained mixed results (Delahanty et al. 2004; Sledjeski
et al. 2005; Vranceanu et al. 2008). Delahanty et al. (2004)
observed that HIV-specific traumatic stress was associated
with poorer ART adherence, but also with lower salivary-
free cortisol in the 30–45 min after awakening and higher
CD4? cell counts. In contrast to these findings, other
studies have observed that HIV-specific traumatic stress as
well as general PTSD symptoms from any trauma
(including HIV) are not independently related to lower
ART adherence after accounting for depressive symptoms
(Sledjeski et al. 2005; Vranceanu et al. 2008). These
discrepant findings highlight the need for further investi-
gations to determine if negative affect and HIV-specific
traumatic stress are independently associated with poorer
ART adherence.
Positive Affect
Positive affect can occur with relatively high frequency in
the midst of a chronic stressor such as living with HIV, and
investigations informed by stress and coping theory have
observed that it serves important adaptive functions (Folk-
man 2008; Folkman and Moskowitz 2000). In contrast to the
narrowing of attention and specific action tendencies that
occurs with the experience of negative affect, positive affect
broadens an individual’s attention focus and behavioral
repertoire (Fredrickson and Branigan 2005). Experimental
evidence also indicates that inducing positive emotions after
a stressful laboratory task promotes enhanced self-regula-
tion (Tice et al. 2007). These beneficial cognitive and
behavioral effects of positive affect may have important
implications for substance use and ART adherence.
Individuals may use stimulants to enhance positive affect
in the short-term. Over time, however, substance use can
erode numerous psychosocial resources, increasing reliance
of substance use as way of coping (Witkiewitz and Marlatt
2004). Positive affect may reinvigorate cognitive-behavioral
coping efforts that are crucial to decrease reliance on sub-
stance use as a means of affect regulation (Wills et al. 1999).
In addition, positive affect assists individuals with building
psychosocial resources that promote resilience in the face of
chronic stress (Fredrickson 2001; Fredrickson et al. 2003),
potentially decreasing the likelihood of continued substance
use or relapse to substance use. Investigations are needed to
examine whether positive affect is independently associated
with decreased stimulant use.
The vast majority of investigations examining psycho-
logical correlates of adherence to medical regimens have
focused on various forms of negative affect and PTSD
symptoms. In fact, to our knowledge no investigation to
date has examined the potential role of positive affect in
promoting ART adherence. One study that excluded indi-
viduals with substance dependence observed that the
association between perceived social support and improved
ART adherence was mediated by increased positive states
of mind (Gonzalez et al. 2004). In another study, Little-
wood et al. (2008) observed that the extent to which
individuals were able to find benefits in living with
HIV/AIDS was associated with improved psychological
adjustment and increased physical activity, but it was
unrelated to ART adherence, alcohol use, or cigarette
smoking. It may be that discrepant findings are partially
due to the fact that measures of these positive psycholog-
ical resources do not directly assess positive affect, which
may be a more robust correlate of ART adherence and
other health behaviors.
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Current Study
The primary goal of the present investigation was to
examine the extent to which HIV-specific traumatic stress,
negative affect, and positive affect are independently
associated with stimulant use and ART adherence among
HIV-positive methamphetamine users. Specifically, we
hypothesized that: (1) HIV-specific traumatic stress and
negative affect would be independently associated with
greater stimulant use and impaired ART adherence; and (2)
positive affect would be independently associated with less
stimulant use and better ART adherence.
Methods
Procedures
To be eligible for participation in the present study, indi-
viduals were required to: (1) be 18 years or older; (2) speak
English; (3) self-identify as man who has sex with men
(MSM) or as transgendered; (4) provide evidence of a
current prescription for an ART regimen; (5) have been
taking an ART regimen for at least 1 month; and (6) report
using methamphetamine during the past 30 days. Partici-
pants were recruited from medical clinics, pharmacies,
community-based organizations that serve HIV-positive
persons, outpatient mental health and substance abuse
treatment programs, other studies for HIV-positive persons,
bars/clubs, and through street outreach. Of the 272 indi-
viduals who completed a brief telephone screen, 132 (49%)
were determined to be eligible. Of these, 122 (92%)
completed a study visit. All measures were administered to
participants in a face-to-face interview format and indi-
viduals were reimbursed for their time with a $30 gift card
to a local grocery store. Study procedures were approved
by the University of California, San Francisco Committee
on Human Research.
Measures
Demographics and Health Status
Age, ethnicity, gender, sexual orientation, education,
income, relationship status, time since HIV diagnosis, time
since starting ART, self-reported CD4? count, and self-
reported detectable HIV viral load were assessed by
questionnaire.
Affect
Positive and negative affect schedule (PANAS). The
intensity of positive and negative affect during the past
week was assessed using the 20-item PANAS (Watson et al.
1988). The PANAS was designed to assess two relatively
independent constructs: high activation positive affect (e.g.,
interested, excited) and high activation negative affect (e.g.,
upset, ashamed). The positive (Cronbach’s a = .92) and
negative (Cronbach’s a = .89) affect subscales of the
PANAS demonstrated good internal consistency.
Impact of event scale (IES). The 15-item IES assesses
how frequently individuals experienced symptoms of intru-
sive thoughts (e.g., I thought about it when I didn’t mean to)
as well as avoidance of triggers for intrusive thoughts (e.g., I
tried to remove it from memory) during the past week with
regard to a specific event. This measure has been consistently
associated with symptoms of PTSD, anxiety, and depression
(Sundin and Horowitz 2002, 2003). In order to assess HIV-
specific traumatic stress, participants rated how frequently
they experienced intrusive thoughts and avoidance with
respect to HIV/AIDS. The IES composite score demon-
strated good internal consistency (Cronbach’s a = .91). As
shown in Table 1, HIV-specific traumatic stress was in the
moderate range (Sundin and Horowitz 2003).
Substance Use
Frequency of stimulant use. Participants reported the number
of days during the past month that they used cocaine, crack,
and methamphetamine. Data were dichotomized to examine
individuals who used these substances at least weekly on
average because weekly stimulant use is independently
associated with elevated HIV viral load and immune acti-
vation in ART-treated HIV-positive persons (Carrico et al.
2008). Participants who reported using for 4 or more days
during the past month were compared to those who reported
using 0–3 days. Because methamphetamine use was part of
the inclusion criteria, it was examined separately.
Binge stimulant use. Participants rated the longest
number of consecutive days that they used cocaine, crack,
and methamphetamine during the past month. Participants
who reported using 2 or more days in a row during the past
month were compared to those who reported no consecu-
tive days of use. Because methamphetamine use was part
of the inclusion criteria, it was examined separately.
Recent stimulant use. In total, 114 participants provided
a urine sample for on-site toxicology screening using a
Redicup test kit (Redwood Toxicology Laboratory, Inc.).
This kit is designed to test for the presence of metabolites
(Tox?) that are indicative of recent use of methamphet-
amine (D-Amphetamine C 1,000 ng/ml) and cocaine
(Benzoylecgonine C 300 ng/ml).
Injection drug use. Participants reported the number of
days that they injected substances during the past month.
Those who reported any injection drug use were compared
to participants who denied injection drug use.
AIDS Behav (2010) 14:769–777 771
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ART Adherence
Self-report measures of ART adherence are often corre-
lated with adherence estimates using more direct measures
(e.g., electronic medication cap monitoring) and self-
reported adherence is generally associated with HIV viral
load (Simoni et al. 2006). The present investigation utilized
the visual analogue scale, a self-report measure of ART
adherence that has been strongly correlated with unan-
nounced pill counts and moderately correlated with HIV
viral load (Giordano et al. 2004; Oyugi et al. 2004).
Because self-report measures are thought to overestimate
adherence, we compared participants who reported being
100% adherent to their ART regimen to those who reported
missing at least one dose of medication during the past
month.
Statistical Analyses
The present investigation utilized binary logistic regression
to examine correlates of substance use and ART adherence.
Because previous investigations have observed that
demographic characteristics such as age and ethnicity may
be important correlates of stimulant use and ART adher-
ence (Gordillo et al. 1999; Grov et al. 2006; Halkitis and
Jerome 2008; Halkitis et al. 2008), we examined the effects
of affective states after controlling for these factors. In the
model examining ART adherence, time since HIV diag-
nosis and time since starting ART were entered as
additional covariates. HIV-specific traumatic stress, nega-
tive affect, and positive affect were entered simultaneously
in the second regression block in order to obtain an
adjusted odds ratio (AOR). This AOR reflects the inde-
pendent effects of each after adjusting for covariates in the
first block. With the exception of age, all continuous pre-
dictors were transformed into z-scores (M = 0, SD = ±1)
to facilitate interpretation of the AOR. Because the
majority of participants were MSM, we conducted separate
analyses to confirm that results were similar after excluding
transgendered participants.
Results
Participant Characteristics
As shown in Table 1, the mean age of participants was 44
(range 26–51). The majority of participants were MSM
(94%). Among the MSM, 84% identified as predominantly
or exclusively gay. The sample was relatively diverse with
respect to ethnicity: 41% Caucasian, 32% African Ameri-
can, 14% Hispanic/Latino, 2% Asian/Pacific Islander, 2%
Native American/Alaskan Native, and 9% of multi-cultural
heritage. Most participants (60%) had completed at least
some college and the modal income was $5,000–$11,999/
year. Individuals had been diagnosed with HIV for an
average for 14 years (range 2–27) and had been taking
ART for 8 years (range .25–20) on average. The mean self-
reported CD4? count was 486 cells/mm3 and most
Table 1 Demographic and clinical characteristics of 122 HIV-posi-
tive individuals on ART (San Francisco, 2007–2008)
Variable n (%)
Gender
Male 115 (94)
Transgender (male to female) 5 (4)
Transgender (female to male) 2 (2)
Sexual orientation
Exclusively heterosexual 3 (3)
Predominantly heterosexual 6 (5)
Bisexual 15 (12)
Predominantly gay 20 (16)
Exclusively gay 78 (64)
Ethnicity
African American 39 (32)
Hispanic/Latino 17 (14)
Asian/Pacific Islander 2 (2)
Native American/Alaskan Native 2 (2)
Caucasian 50 (41)
Multi-cultural 12 (9)
Education
Did not graduate high school 17 (14)
High school graduate 31 (26)
Some college 42 (34)
College graduate or greater 32 (26)
Income
\$5,000 11 (9)
$5,000–$11,999 54 (44)
$12,000–$15,999 26 (21)
$16,000–$24,999 20 (17)
$25,000–$74,999 11 (9)
Currently in a primary relationship 48 (39)
Undetectable HIV viral load (self report) 74 (61)
M (SD)
Age 44 (6)
Time since HIV diagnosis (in years) 14 (6)
Time since starting ART (in years) 8 (6)
CD4? count (self report) 486 (603)
Positive affect (PANAS)a 33.0 (8.5)
Negative affect (PANAS)a 22.5 (8.4)
HIV-specific traumatic stress (IES)b 25.6 (18.4)
a Possible range of scores was 10–50
b Possible range of scores was 0–75
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participants (61%) reported having an undetectable HIV
viral load.
Preliminary Analyses
Because individuals often use multiple stimulants, we
began by examining the associations between indices of
methamphetamine and cocaine/crack use. Use of cocaine/
crack at least weekly was not associated with using
methamphetamine at least weekly (OR = .55, P [ .05;
95% CI = .26–1.18). Binge use of cocaine or crack was
also not associated with binge use of methamphetamine
(OR = .51, P [ .05; 95% CI = .24–1.11). However,
individuals who were Tox? for cocaine/crack were sig-
nificantly less likely to be Tox? for methamphetamine
(OR = .30, P \ .05; 95% CI = .12–.76).
Next, in order to establish the validity of our self-
reported measure of adherence, we examined correlations
with measures of self-reported immune status that have
previously been demonstrated to be reliable and valid
indicators of actual values (Kalichman et al. 2000). Using
Spearman correlations, reporting 100% ART adherence
during the past month was associated with higher self-
reported CD4? count (r = .22, P \ .05) and marginally
associated with a decreased likelihood of reporting a
detectable HIV viral load (r = -.18, P = .054).
Correlates Methamphetamine Use
During the past month, 53% of participants reported using
methamphetamine at least weekly and 63% reported binge
use of methamphetamine. Approximately 32% of partici-
pants were Tox? for methamphetamine at their study visit.
Compared to Caucasian participants, African American
individuals were significantly less likely to report use of
methamphetamine at least weekly (AOR = .15, P = .01)
and less likely to report binge use of methamphetamine
(AOR = .10, P \ .01). African American participants
were also marginally less likely to be Tox? for metham-
phetamine at their study visit (AOR = .37, P = .06).
Compared to Caucasians, Hispanic/Latino participants
were less likely to report binge use of methamphetamine
(AOR = .20, P \ .05) and were less likely to be Tox? for
methamphetamine at their study visit (AOR = .12,
P \ .05). Elevated negative affect was independently
associated with a greater likelihood of reporting metham-
phetamine use at least weekly (AOR = 1.76, P \ .05), but
was not significantly related to reporting binge use or being
Tox? for methamphetamine. Elevated HIV-specific trau-
matic stress was independently associated with a decreased
likelihood of being Tox? for methamphetamine
(AOR = .52, P \ .05), but was unrelated to indices of self-
reported methamphetamine use. Results of these logistic
regression analyses are summarized in Table 2. Findings
were comparable when only data from MSM were
examined.
Correlates of Cocaine/Crack Use
During the past month, 33% of participants reported using
cocaine/crack at least weekly and 33% reported binge use
of cocaine/crack. Approximately 37% of participants were
Tox? for cocaine/crack at their study visit. Compared to
Caucasian participants, African American individuals were
significantly more likely to report cocaine/crack use at least
weekly (AOR = 3.66, P \ .05), report binge use of
cocaine/crack (AOR = 2.93, P \ .05), and be Tox? for
cocaine/crack (AOR = 5.19, P \ .01). In addition, ele-
vated HIV-specific traumatic stress was independently
associated with a greater likelihood of reporting cocaine/
Table 2 Logistic regression analyses for indices of methamphetamine use
Predictor variable At least weekly Binge use Tox? urine screen
AOR 95% CI AOR 95% CI AOR 95% CI
Age .95 .89–1.01 .93 .87–1.00 .95 .89–1.01
Caucasian 1.00 Reference 1.00 Reference 1.00 Reference
African American .15** .06–.41 .10** .03–.29 .37 .13–1.04
Hispanic/Latino .39 .12–1.33 .20* .05–.78 .12* .02–.64
Other ethnic minority .64 .19–2.19 .47 .11–1.98 .37 .09–1.46
Positive affect (PANAS) 1.21 .74–1.98 .98 .58–1.64 1.00 .57–1.75
Negative affect (PANAS) 1.76* 1.02–3.03 1.54 .86–2.75 1.60 .93–2.78
HIV-specific traumatic stress (IES) .73 .46–1.15 .75 .46–1.22 .52* .30–.90
Analyses included all available data from the 122 participants
AOR adjusted odds ratio
* P \ .05; ** P B .01
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crack use at least weekly (AOR = 2.18, P \ .01), report-
ing binge use of cocaine/crack (AOR = 1.86, P \ .01),
and being Tox? for cocaine/crack (AOR = 1.74, P \ .05).
Results of these logistic regression analyses are summa-
rized in Table 3. Findings were comparable when only data
from MSM were examined.
Correlates of Injection Drug Use and ART Adherence
Approximately 44% of participants reported injection drug
use in the past month, and of these the vast majority (85%)
reported that they had injected only methamphetamine.
Elevated positive affect was independently associated with
a decreased likelihood of reporting injection drug use
during the past month (AOR = .62, P \ .05). For ART
adherence, *26% of participants reported taking every
medication dose in the past month. Higher positive affect
was independently associated with increased likelihood of
reporting perfect ART adherence during the past month
(AOR = 1.79, P \ .05). We also replicated findings for
ART adherence in a secondary analysis using a less strin-
gent cut-off. Positive affect was marginally associated with
an higher odds of reporting ART adherence that was
greater than or equal to 90% in the past month
(AOR = 1.63, P = .051; 95% CI = 1.00–2.65). Results of
logistic regression analyses examining injection drug use
and 100% ART adherence are summarized in Table 4.
Findings were comparable when only data from MSM were
examined.
Discussion
The present investigation provides empirical support for
the self medication hypothesis (Khantzian 1997), which
posits that difficulties with affect regulation are a key
determinant of substance abuse. We observed that HIV-
specific traumatic stress was independently associated with
increased likelihood of reporting at least weekly use as well
as binge use of cocaine/crack. In addition, when examining
Table 3 Logistic regression analyses for indices of cocaine/crack use
Predictor variable At least weekly Binge use Tox? urine screen
AOR 95% CI AOR 95% CI AOR 95% CI
Age 1.06 .99–1.13 1.06 .99–1.13 1.05 .98–1.13
Caucasian 1.00 Reference 1.00 Reference 1.00 Reference
African American 3.66* 1.31–10.23 2.93* 1.08–7.96 5.19** 1.81–14.87
Hispanic/Latino 1.77 .43–7.29 2.21 .58–8.42 2.37 .60–9.42
Other ethnic minority 3.06 .79–11.77 1.93 .50–7.36 2.67 .66–10.79
Positive affect (PANAS) .78 .47–1.29 .79 .48–1.30 .79 .48–1.31
Negative affect (PANAS) .77 .45–1.33 .85 .51–1.44 .87 .51–1.47
HIV-specific traumatic stress (IES) 2.18** 1.33–3.58 1.86** 1.16–2.99 1.74* 1.07–2.82
Analyses included all available data from the 122 participants
AOR adjusted odds ratio
* P \ .05; ** P B .01
Table 4 Logistic regression
analyses for injection drug use
and ART adherence
Analyses included all 122
participants
AOR adjusted odds ratio
* P \ .05
Predictor variable Injection drug use 100% ART adherence
AOR 95% CI AOR 95% CI
Age 1.01 .95–1.07 .99 .92–1.07
Caucasian 1.00 Reference 1.00 Reference
African American .48 .19–1.18 1.45 .50–4.24
Hispanic/Latino .52 .16–1.71 .90 .21–3.77
Other ethnic minority .65 .20–2.10 4.00* 1.09–14.70
Time since HIV diagnosis .96 .88–1.05
Time since starting ART 1.06 .97–1.17
Positive affect (PANAS) .62* .38–.99 1.79* 1.06–3.03
Negative affect (PANAS) .89 .55–1.43 1.23 .71–2.14
HIV-specific traumatic stress (IES) .85 .55–1.31 1.56 .96–2.55
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affective correlates of urine toxicology screening results,
an interesting pattern emerged. Although HIV-specific
traumatic stress was associated with a decreased likelihood
of being Tox? for methamphetamine, this may be partially
due to the fact that individuals with elevated HIV-specific
traumatic stress were more likely to be Tox? for cocaine at
the study visit. Because those with elevated HIV-specific
traumatic stress were more likely to have recently used
cocaine or crack, this appears to have resulted in artificially
lower rates of recent methamphetamine use. This is further
supported by the fact that HIV-specific traumatic stress was
unrelated to indices of self-reported methamphetamine use
during the past month. With regard to other correlates of
methamphetamine use, we observed that elevated negative
affect was independently associated with at least weekly
use but was unrelated to binge use or being Tox? for
methamphetamine at the study visit. Because inclusion
criteria for the study required that individuals report using
methamphetamine at least once in the past month, this
selected for a sample that reports more frequent metham-
phetamine use. The restricted range may have decreased
the likelihood of identifying robust affective correlates of
methamphetamine use.
Stress and coping theory (Folkman 2008; Folkman and
Moskowitz 2000) proposes that positive affect serves
important adaptive functions among individuals managing a
chronic stressor such as living with HIV, and findings from
the present investigation support this theoretical conceptu-
alization. Positive affect was independently associated with
a decreased likelihood of engaging in injection drug use
during the past month. A previous investigation observed
that positive affect may promote cognitive-behavioral cop-
ing efforts that assist individuals with decreasing substance
use (Wills et al. 1999), and positive affect may also build the
capacity of individuals to refrain from engaging in injection
drug use. Lending further support to stress and coping the-
ory, we observed that positive affect was independently
associated with improved ART adherence. Prior studies
have consistently reported that HIV-positive stimulant users
are at substantially elevated risk for impaired ART adher-
ence (Carrico et al. 2007; Hinkin et al. 2007; Johnson et al.
2008), but poor ART adherence rates are not universally
observed in this population. Positive affect may be an
important source of psychological resilience among HIV-
positive methamphetamine users that assists individuals
with effectively managing difficult ART regimens. Taken
together, these data provide some preliminary evidence that
positive affect is independently associated with a decreased
likelihood of engaging in injection drug use and an increased
likelihood of achieving perfect ART adherence among HIV-
positive methamphetamine users.
Findings from the present investigation also underscore
the importance of attending to ethnic differences in the use
of various stimulants among MSM. Previous investigations
that recruited MSM at gay-identified venues have reported
discrepant findings regarding ethnic differences in sub-
stance use (Grov et al. 2006; Halkitis and Jerome 2008;
Halkitis et al. 2008). Using large samples of MSM
recruited at gay community events in New York City and
Los Angeles, Grov et al. (2006) observed that Asian/Pacific
Islander men were less likely to report using a variety of
substances, but there were no other ethnic differences in
substance use. In contrast, other investigations with MSM
in New York City have provided some contradictory
findings. Although one study observed that African
American or Hispanic/Latino participants were more likely
to report using methamphetamine (Halkitis et al. 2008),
other data suggest that African Americans are significantly
less likely to report using methamphetamine compared to
Caucasian or Hispanic/Latino participants (Halkitis and
Jerome 2008). Results of the present investigation indicate
that African American and Hispanic/Latino individuals
may be less likely to report methamphetamine use and to
be Tox? for methamphetamine. On the other hand, we
observed that African Americans were more likely to
report using cocaine/crack and were more likely to be
Tox? for cocaine at the study visit. Although findings from
this convenience sample of HIV-positive methamphet-
amine users should be interpreted with caution, this
highlights that there may be important ethnic differences in
the frequency and/or patterns of the use of various stimu-
lants in this population.
Taken together, these data provide some indication that
HIV-specific traumatic stress may be an especially impor-
tant psychological factor that is associated with indicators of
more problematic cocaine/crack use among HIV-positive
methamphetamine users. However, it is unclear whether
elevated HIV-specific traumatic stress reflects the influence
of specific HIV-related traumatic stressors (e.g., HIV diag-
nosis) or if it is more indicative of the cumulative effects of
living with this highly stigmatized, chronic illness. This
issue should be examined in future studies. Further investi-
gations should also attempt to determine whether HIV-
specific traumatic stress is associated with indices of stim-
ulant use after controlling for general PTSD symptoms that
stem from other traumatic events that are not related to HIV.
It is also noteworthy that the present investigation defined
binge use as using stimulants for 2 or more days in a row
during the past month. Although even relatively short binges
are thought to be related to ART non-adherence and
potentially increased sexual risk taking, research with larger
samples is needed to more adequately differentiate between
binge and chronic stimulant use. Results should also be
interpreted with caution given the cross-sectional design and
small sample size of the present study. Because we exam-
ined affective correlates of stimulant use and ART
AIDS Behav (2010) 14:769–777 775
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adherence, these data do not provide evidence of a causal
relationship. For example, it is plausible that recent sub-
stance use may have resulted in exacerbations in HIV-
specific traumatic stress and negative affect as well as
decreases in positive affect. Difficulties with affect regula-
tion may also be a marker for more severe dependence
symptoms, but we were unable to examine this possibility
because the present study did not include interview-based
methods of diagnosing stimulant abuse or dependence.
Despite these limitations, the present study may assist with
the development of innovative psychological treatments
designed to meet the needs of diverse groups of HIV-posi-
tive stimulant users on ART. Specifically, findings highlight
that interventions designed to reduce HIV-specific traumatic
stress as well as enhance positive affect may be efficacious
in decreasing stimulant use and improving ART adherence.
Future studies should attempt to replicate these findings with
larger samples and examine the clinical relevance of inter-
ventions designed to improve affect regulation among HIV-
positive stimulant users.
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